|
US2011070319A1
|
|
Bifeprunox doses for treating schizophrenia
|
|
ZA201001596B
|
|
5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb receptor agonists
|
|
US2010120752A1
|
|
Muscarinic agonists to treat impulse control disorders
|
|
TW201028168A
|
|
Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
|
|
TW201026708A
|
|
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
|
|
WO2010060742A1
|
|
Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
|
|
TW201010981A
|
|
Synthesis of 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamidine derivatives
|
|
TW201006826A
|
|
Method of treatment using eprosartan
|
|
TW201008924A
|
|
Fluoro-substituted 3,4-diaryl-4,5-dihydro-1H-pyrazole-1-carboxamidine derivatives having CB1-antagonistic activity
|
|
TW200948798A
|
|
(5R)-1, 5-diaryl-4, 5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CB1-antagonistic activity
|
|
ZA200901473B
|
|
Sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
|
|
WO2009106516A1
|
|
Compositions, kits and methods for a titration schedule for pardoprunox compounds
|
|
US2009215796A1
|
|
Compositions, Kits and Methods for a Titration Schedule for Pardoprunox Compounds
|
|
TW200944205A
|
|
Compositions, kits and methods of a titration schedule for pardoprunox compounds
|
|
ZA200900053B
|
|
Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
|
|
ZA200810478B
|
|
Oral pharmaceutical composition of a poorly water-soluble active substance
|
|
ZA200810239B
|
|
Combination preparations comprising SLV308 and a L-Dopa
|
|
CN101821389A
|
|
Novel process for separating and determining the viral load in a pancreatin sample
|
|
ZA200809208B
|
|
Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
|
|
BRPI0816950A2
|
|
Compounds, drug, pharmaceutical composition, and use of a compound
|
